Analyst Terence Flynn of Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on BMY stock, giving a Buy rating on January 12.Invest with ...

We recently compiled a list of the 15 Stocks to Invest in with Steady Dividends. In this article, we are going to take a look ...

Ameritas Advisory Services LLC increased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 9.4% in ...

Amsterdam, the Netherlands, 28 January 2025 - Freya Pharma Solutions, [Freya Pharma, or the Company], a pharmaceutical ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

The latest decision makes Sanofi's Sarclisa the first anti-CD38 therapy for transplant-ineligible patients with front-line ...

According to our calculations, a $1000 investment made in January 2015 would be worth $4,020.91, or a gain of 302.09%, as of January 27, 2025, and this return excludes dividends but includes price ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

K-Bio leaders pursue U.S. factories and conferences during Lunar New Year K-Bio executives opt for international business ...

Several New Jersey-based companies have earned high rankings in Newsweek’s 2024 list of America’s Most Trustworthy Companies.

The FDA accepts and grants priority review to Replimune's BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on Jul.